ARCUTIS BIOTHERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$800.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-25
- ARCUTIS BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$800.00K, a 102.00% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $40.10M, a 24.91% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $53.40M, a 26.24% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $72.40M, a 61.97% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | -$800.00K 10-K · filed 2026-02-25 |
| 2024-12-31 | $40.10M 10-K · filed 2026-02-25 |
| 2023-12-31 | $53.40M 10-K · filed 2025-02-25 |
| 2022-12-31 | $72.40M 10-K · filed 2024-02-27 |
| 2021-12-31 | $44.70M 10-K · filed 2023-02-28 |
| 2020-12-31 | $30.70M 10-K · filed 2022-02-22 |
| 2019-12-31 | $9.60M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |